


Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. *N Engl J Med* 2005;353:2550-8.

SELENA-SLEDAI Flare Composite



SELENA-SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) INSTRUMENT SCORE

Check box: if descriptor is present at the time of visit or in the preceding 10 days.

Wt	Present	Descriptor	Definition
8	<input type="checkbox"/>	Seizure	Recent onset (last 10 days). Exclude metabolic, infectious or drug cause, or seizure due to past irreversible CNS damage.
8	<input type="checkbox"/>	Psychosis	Altered ability to function in normal activity due to severe disturbance in the perception of reality. Include hallucinations; incoherence; marked loose associations; impoverished thought content; marked illogical thinking; bizarre, disorganized or catatonic behavior. Exclude uremia and drug causes.
8	<input type="checkbox"/>	Organic brain syndrome	Altered mental function with impaired orientation, memory or other intellectual function, with rapid onset and fluctuating clinical features. Include clouding of consciousness with reduced capacity to focus, and inability to sustain attention to environment, plus at least 2 of the following: perceptual disturbance, incoherent speech, insomnia or daytime drowsiness, or increased or decreased psychomotor activity. Exclude metabolic, infectious or drug causes.
8	<input type="checkbox"/>	Visual disturbance	Retinal and eye changes of SLE. Include cytoid bodies, retinal hemorrhages, serous exudate or hemorrhages in the choroid, optic neuritis, scleritis or episcleritis. Exclude hypertension, infection or drug causes.
8	<input type="checkbox"/>	Cranial nerve disorder	New onset of sensory or motor neuropathy involving cranial nerves. Include vertigo due to lupus.
8	<input type="checkbox"/>	Lupus headache	Severe persistent headache: may be migrainous, but must be nonresponsive to narcotic analgesia.
8	<input type="checkbox"/>	CVA	New onset of cerebrovascular accident(s). Exclude arteriosclerosis or hypertensive causes.
8	<input type="checkbox"/>	Vasculitis	Ulceration, gangrene, tender finger nodules, periungual infarction, splinter hemorrhages, or biopsy or angiogram proof of vasculitis.
4	<input type="checkbox"/>	Arthritis	More than 2 joints with pain and signs of inflammation (i.e., tenderness, swelling or effusion).
4	<input type="checkbox"/>	Myositis	Proximal muscle aching/weakness, associated with elevated creatine phosphokinase/aldolase or electromyogram changes or a biopsy showing myositis.
4	<input type="checkbox"/>	Urinary casts	Heme-granular or red blood cell casts.
4	<input type="checkbox"/>	Hematuria	>5 red blood cells/high power field. Exclude stone, infection or other cause.
4	<input type="checkbox"/>	Proteinuria	New onset or recent increase of more than 0.5 gm/24 hours.
4	<input type="checkbox"/>	Pyuria	>5 white blood cells/high power field. Exclude infection.
2	<input type="checkbox"/>	Rash	Ongoing inflammatory lupus rash.
2	<input type="checkbox"/>	Alopecia	Ongoing abnormal, patchy or diffuse loss of hair due to active lupus.
2	<input type="checkbox"/>	Mucosal ulcers	Ongoing oral or nasal ulcerations due to active lupus.
2	<input type="checkbox"/>	Pleurisy	Classic and severe pleuritic chest pain or pleural rub or effusion or new pleural thickening due to lupus.
2	<input type="checkbox"/>	Pericarditis	Classic and severe pericardial pain or rub or effusion, or electrocardiogram confirmation.
2	<input type="checkbox"/>	Low complement	Decrease in CH50, C3 or C4 below the lower limit of normal for testing laboratory.
2	<input type="checkbox"/>	Increased DNA binding	>25% binding by Farr assay or above normal range for testing laboratory.
1	<input type="checkbox"/>	Fever	>38°C. Exclude infectious cause.
1	<input type="checkbox"/>	Thrombocytopenia	<100,000 platelets/mm ³ .
1	<input type="checkbox"/>	Leukopenia	<3,000 white blood cells/mm ³ . Exclude drug causes.

_____ **TOTAL SCORE** (Sum of weights next to descriptors marked present)

Mild or Moderate Flare

- Change in SELENA-SLEDAI instrument score of 3 points or more (but not to more than 12)
- New/worse:
 - Discoid, photosensitive, profundus, cutaneous vasculitis, bullous lupus
 - Nasopharyngeal ulcers
 - Pleuritis
 - Pericarditis
 - Arthritis
 - Fever (SLE)
- Increase in prednisone, but not to >0.5 mg/kg/day
- Added NSAID or hydroxychloroquine for SLE activity
- ≥1.0 increase in PGA score, but not to more than 2.5

Severe Flare

- Change in SELENA-SLEDAI instrument score to greater than 12
- New/worse:
 - CNS-SLE
 - Vasculitis
 - Nephritis
 - Myositis
 - Plt <60,000
 - Hemolytic anemia: Hb <70 g/L or decrease in Hb >30 g/L
- Requiring:** double prednisone, or prednisone increase to >0.5 mg/kg/day, or hospitalization
- Increase in prednisone to >0.5 mg/kg/day
- New cyclophosphamide, azathioprine, methotrexate for SLE activity
- Hospitalization for SLE activity
- Increase in Physician's Global Assessment score to >2.5

APPENDIX Table: Enrollment by Participating Clinical Site.

Clinical Site:	OC		Placebo		Total	
	N	(%)	N	(%)	N	(%)
Johns Hopkins University School of Medicine, Baltimore, MD	29	(32%)	26	(28%)	55	(30%)
Hospital for Joint Diseases/Bellevue/ NYU School of Medicine, New York, NY	17	(19%)	18	(20%)	35	(19%)
University of California–Los Angeles, Los Angeles, CA	15	(16%)	14	(15%)	29	(16%)
Hospital for Special Surgery, New York, NY	10	(11%)	10	(11%)	20	(11%)
St. Luke’s-Roosevelt Hospital Center, New York, NY	4	(4%)	4	(4%)	8	(4%)
Louisiana State University Health Sciences Center, Shreveport, LA	3	(3%)	4	(4%)	7	(4%)
University of Michigan, Ann Arbor, MI	4	(4%)	3	(3%)	7	(4%)
University of North Carolina at Chapel Hill, Chapel Hill, NC	3	(3%)	3	(3%)	6	(3%)
University of Pennsylvania, Philadelphia, PA	3	(3%)	2	(2%)	5	(3%)
University of Texas–Houston, Houston, TX	2	(2%)	2	(2%)	4	(2%)
Rheumatology Associates of Long Island, Port Jefferson Station, NY	1	(1%)	1	(1%)	2	(1%)
University of California–San Francisco, San Francisco, CA	0	-	2	(2%)	2	(1%)
Albert Einstein College of Medicine/ Montefiore Medical Center, Bronx, NY	0	-	1	(1%)	1	(<1%)
Medical College of Wisconsin, Milwaukee, WI	0	-	1	(1%)	1	(<1%)
Oklahoma Medical Research Foundation, Oklahoma City, OK	0	-	1	(1%)	1	(<1%)
TOTAL	91		92		183	